Meeder Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Meeder Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,535	Closed	-$7K	–	1824
2021 Q3	$7K	Hold	1,535	–	–	﹤0.01%	1805
2021 Q2	$7K	Buy	+1,535	New	+$7.39K	﹤0.01%	1829
2020 Q1	–	Sell	-9,857	Closed	-$40K	–	2439
2019 Q4	$40K	Buy	9,857 +8,705	+756%	+$33.5K	﹤0.01%	1093
2019 Q3	$3K	Buy	+1,152	New	+$3.57K	﹤0.01%	1882
2017 Q3	–	Sell	-101	Closed	-$2K	–	1701
2017 Q2	$2K	Sell	101 -13	-11%	-$201	﹤0.01%	1409
2017 Q1	$2K	Buy	+114	New	+$1.69K	﹤0.01%	1379

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's LXRX Position: Q4 2021 in Review

Meeder Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2021, closing a stake of 1,535 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in LXRX in Q1 2017 and held it in 6 quarters. The position peaked at $40K in Q4 2019. 110 funds tracked by Wall St. Rank hold LXRX as of Q4 2021.

Meeder Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 1,535 Lexicon Pharmaceuticals shares in Q4 2021, an estimated $7K.
Meeder Asset Management first reported a position in Lexicon Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Meeder Asset Management's Lexicon Pharmaceuticals position peaked at $40K in Q4 2019.
110 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.